Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Naratriptan
Drug ID BADD_D01535
Description Naratriptan is a triptan drug that is selective for the 5-hydroxytryptamine1 receptor subtype. It is typically used for the treatment of migraine headaches.
Indications and Usage For the acute treatment of migraine attacks with or without aura in adults.
Marketing Status approved; investigational
ATC Code N02CC02
DrugBank ID DB00952
KEGG ID D08255
MeSH ID C106783
PubChem ID 4440
TTD Drug ID D0T3KI
NDC Product Code 69452-340; 69452-341; 23155-054; 42043-130; 42043-131; 23155-055; 50090-6162; 0054-0278; 0054-0279
UNII QX3KXL1ZA2
Synonyms naratriptan | N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide | GR 85548A | naratriptan hydrochloride | N-methyl-3-(1-methyl-4-piperidyl)indole-5-ethanesulfonamide monohydrochloride | 1H-indole-5-ethanesulfonamide, N-methyl-3-(1-methyl-4-piperidinyl)-, monohydrochloride | Naramig | Amerge | Colatan
Chemical Information
Molecular Formula C17H25N3O2S
CAS Registry Number 121679-13-8
SMILES CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyelonephritis20.01.09.001; 11.01.14.002--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.0010.003367%Not Available
Rash macular23.03.13.003--Not Available
Rash pruritic23.03.13.030--Not Available
Red blood cell count13.01.05.020--Not Available
Restlessness19.11.02.002; 17.02.05.021--
Retinal vein occlusion24.01.07.006; 06.10.01.0100.006733%Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Rhinitis allergic22.04.04.003; 10.01.04.003--
Salivary gland enlargement07.06.03.002--Not Available
Sedation17.02.04.005--Not Available
Seizure17.12.03.001--
Sensory loss17.02.07.007--Not Available
Serotonin syndrome17.05.02.004; 15.05.04.016; 12.03.01.041--Not Available
Shock24.06.02.002--Not Available
Sialoadenitis11.01.04.002; 07.06.04.002--
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Sleep disorder19.02.04.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Stillbirth18.01.02.002; 08.04.01.0060.005050%Not Available
Stomatitis07.05.06.005--
Subarachnoid haemorrhage24.07.04.004; 12.01.10.011; 17.08.01.010--Not Available
Swelling08.01.03.015--Not Available
Syncope17.02.04.008; 02.11.04.015; 24.06.02.012--
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombocytopenia01.08.01.002--Not Available
The 6th Page    First    Pre   6 7 8    Next   Last    Total 8 Pages